scholarly journals Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism

2004 ◽  
Vol 19 (4) ◽  
pp. 892-897 ◽  
Author(s):  
J. J. Kazama ◽  
K. Omori ◽  
N. Higuchi ◽  
N. Takahashi ◽  
Y. Ito ◽  
...  
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Dialysis Patients ◽  
Intact Pth

Assessing acute parathyroid responsiveness in hemodialysis patients by measuring intact parathyrin in pre- and post-dialysis serum

1991 ◽  
Vol 37 (7) ◽  
pp. 1216-1220 ◽  
Author(s):  
Beverly A Dilena ◽  
Graham H White
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Whole Blood ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Total Calcium ◽  
Dialysis Patients ◽  
Intact Pth ◽  
Set Point ◽  
Patients At Risk ◽  
Analytical Imprecision

Abstract We measured pre- and post-dialysis concentrations of ionized calcium (iCa) in whole blood, total calcium (tCa) in plasma, and intact parathyrin (PTH) in serum of 19 patients undergoing maintenance hemodialysis. Plasma tCa was inappropriately increased relative to iCa in 63% of the specimens; the iCa correlated with the PTH concentration in 12 of 19 pre-dialysis specimens, whereas tCa correlated with PTH in only five patients. During dialysis, 16 patients had analytically significant changes in iCa (i.e., exceeded the analytical imprecision of 0.04 mmol/L). Pre- and post-dialysis concentrations of PTH were normal in six patients, four of whom showed a detectable response to changes in iCa. Ten patients had increased PTH in at least one specimen; of these, eight had responsive parathyroid glands. Five of the 16 patients had an increased set point for calcium. The minimal PTH responses of two patients suggested refractory hyperparathyroidism. We conclude that routine estimation of iCa, rather than tCa, in dialysis patients markedly improves the identification of patients at risk for secondary hyperparathyroidism, and that measurement of intact PTH in pre- and post-dialysis serum offers a simple means of assessing parathyroid responsiveness in dialysis patients.

Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism

2013 ◽  
Vol 18 (3) ◽  
pp. 507-514 ◽  
Author(s):  
Ema J. Jamaluddin ◽  
Abdul Halim Abdul Gafor ◽  
Loo Chee Yean ◽  
Rizna Cader ◽  
Rozita Mohd ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Secondary Hyperparathyroidism ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Dialysis Patients

Management of secondary hyperparathyroidism of dialysis patients

Nephrology ◽  
2003 ◽  
Vol 8 ◽  
pp. S53-S57 ◽  
Author(s):  
Tadao AKIZAWA ◽  
Motohiro KAMIMURA ◽  
Masahide MIZOBUCHI ◽  
Kazuhiro SHIIZAKI ◽  
Shinji SUMIKADO ◽  
...  
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Dialysis Patients

The Use of Cinacalcet Hydrochloridevs.Parathyroidectomy for Treatment of Secondary Hyperparathyroidism in Dialysis Patients Refractory to Alfacalcidol

2011 ◽  
pp. P3-97-P3-97
Author(s):  
Lilit V Egshatyan ◽  
Liudmila Ya Rozhinskaya ◽  
Nikolai S Kuznecov ◽  
Ekaterina A Pigarova
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Dialysis Patients

scholarly journals FP400INFLUENCE OF THE SECONDARY HYPERPARATHYROIDISM IN IRON REQUIREMENTS IN DIALYSIS PATIENTS ON ERYTHROPOIESIS-STIMULATING AGENT THERAPY. A PROSPECTIVE CONTROLLED STUDY

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii203-iii203
Author(s):  
Miguel Uriol Rivera ◽  
Sheila Cabello Pelegrin ◽  
Antonio Corral Baez ◽  
Sonia Jimenez Mendoza ◽  
Juan Rey Valeriano ◽  
...  
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Controlled Study ◽  
Dialysis Patients ◽  
Prospective Controlled Study

scholarly journals Pre-operative Localisation of the Parathyroid Glands in Secondary Hyperparathyroidism: A Retrospective Cohort Study

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Takahisa Hiramitsu ◽  
Toshihide Tomosugi ◽  
Manabu Okada ◽  
Kenta Futamura ◽  
Makoto Tsujita ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Cohort Study ◽  
Parathyroid Hormone ◽  
Secondary Hyperparathyroidism ◽  
Retrospective Cohort ◽  
Parathyroid Glands ◽  
Imaging Modalities ◽  
Intact Parathyroid Hormone ◽  
Intact Pth ◽  
Persistent Hyperparathyroidism

Abstract Complete parathyroidectomy (PTx) is essential during total PTx for secondary hyperparathyroidism (SHPT) to prevent recurrent and persistent hyperparathyroidism. Pre-operative imaging evaluations, including computed tomography (CT), ultrasonography (US), and Tc-99m sestamibi (MIBI) scans, are commonly performed. Between June 2009 and January 2016, 291 patients underwent PTx for SHPT after pre-operative evaluations involving CT, US, and MIBI scans, and the diagnostic accuracies of these imaging modalities for identifying the parathyroid glands were evaluated in 177 patients whose intact parathyroid hormone (PTH) levels were <9 pg/mL after the initial PTx. Additional PTx procedures were performed on 7 of 114 patients whose intact PTH levels were >9 ng/mL after PTx, and the diagnostic validities of the imaging modalities for the remnant parathyroid glands were evaluated. A combination of CT, US, and MIBI scans achieved the highest diagnostic accuracy (75%) for locating bilateral upper and lower parathyroid glands before initial PTx. The accuracies of CT, US, and MIBI scans with respect to locating remnant parathyroid glands before additional PTx were 100%, 28.6%, and 100%, respectively. A combination of CT, US, and MIBI scans is useful for initial PTx for SHPT, and CT and MIBI scans are useful imaging modalities for additional PTx procedures.

scholarly journals Transperitoneal Calcium Balance in Anuric Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Chieko Hamada ◽  
Yasuhiko Tomino
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Biochemical Parameters ◽  
Calcium Balance ◽  
Automated Peritoneal Dialysis ◽  
Dialysis Patients ◽  
Intact Pth ◽  
Rapid Removal ◽  
The Difference ◽  
Short Time

Backgrounds. Calcium (Ca) and bone metabolism in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients show a remarkable difference depending on dialysis modalities. The levels of serum Ca and phosphate (P) in HD patients fluctuate contributing to the intermittent and rapid removal of plasma solute unlike in CAPD. Characteristics of plasma solute transport in automated peritoneal dialysis (APD) patients are resembled with that in HD. The purpose of the present study was to examine the difference of transperitoneal Ca removal between APD and CAPD anuric patients.Subjects and Methods. Twenty-three APD anuric patients were enrolled in this study. Biochemical parameters responsible for transperitoneal Ca removal in 24-hour and 4-hour peritoneal effluents were analyzed on CAPD and APD.Results. Transperitoneal Ca removal on APD was smaller compared with that on CAPD. The Ca removal was related to the ultrafiltration during short-time dwell. Decrease of the Ca removal during NPD induced by short-time dialysate dwell caused negative or small Ca removal in APD patients. The levels of intact PTH were increased at the end of PET.Conclusion. It appears that short-time dwell and frequent dialysate exchanging might suppress the transperitoneal Ca removal in anuric APD patients.

Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients

2008 ◽  
Vol 28 (2_suppl) ◽  
pp. 42-46 ◽  
Author(s):  
Jean Francis ◽  
David B. Simon ◽  
Peter Jeurgensen ◽  
Fredric O. Finkelstein
Keyword(s):  
Vitamin D ◽  
Peritoneal Dialysis ◽  
Secondary Hyperparathyroidism ◽  
Hormone Secretion ◽  
Phosphate Binders ◽  
Serum Phosphate Level ◽  
Dialysis Patients ◽  
Intravenous Vitamin ◽  
Stage Renal Disease ◽  
End Stage

Secondary hyperparathyroidism is a common complication in patients with end-stage renal disease. It has been associated with increased cardiovascular events and mortality. Traditional therapy has been based on vitamin D analogs and phosphate binders; but these therapies often do not control secondary hyperparathyroidism, particularly in peritoneal dialysis patients for whom phosphate clearances are limited and intravenous vitamin D is impractical. Cinacalcet, a calcimimetic, suppresses parathormone secretion by interacting with the calcium-sensing receptor on the surface of parathyroid gland cells. The resulting suppression of parathyroid hormone secretion produces a reduction in serum phosphate level and CaxPO4 product. The present paper reviews the efficacy of cinacalcet in the management of secondary hyperparathyroidism in peritoneal dialysis patients.

Sign in / Sign up

Export Citation Format

Share Document